Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | APAF1 | O14727 | 1/20 | 0.51 |
| ▸ | TDP2 | O95551 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 1/20 | 0.51 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.51 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.51 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | KDM6B | O15054 | 1/20 | 0.49 |
| ▸ | KDM6A | O15550 | 1/20 | 0.49 |
| ▸ | TET3 | O43151 | 1/20 | 0.49 |
| ▸ | KDM4A | O75164 | 1/20 | 0.49 |
| ▸ | KDM4B | O94953 | 1/20 | 0.49 |
| ▸ | KDM5C | P41229 | 1/20 | 0.49 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.49 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27214228 | 0.87 | KDM4E (0.51) | MEN1KMT2AAPAF1TDP2ALDH1A1 | |
| SCHEMBL30553415 | 0.87 | KDM4E (0.51) | MEN1KMT2AAPAF1TDP2ALDH1A1 | |
| SCHEMBL15757867 | 0.85 | KDM4E (0.68) | MEN1KMT2AAPAF1TDP2ALDH1A1 | |
| SCHEMBL27767795 | 0.83 | KDM4E (0.64) | KDM4EL3MBTL1KDM6BKDM6ATET3 | |
| SCHEMBL15758767 | 0.83 | KDM4E (0.71) | MEN1KMT2AAPAF1TDP2ALDH1A1 | |
| SCHEMBL11912045 | 0.81 | MEN1 (0.51) | MEN1KMT2AALDH1A1KDM4EL3MBTL1 | |
| SCHEMBL29462403 | 0.81 | KDM4E (0.73) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| SCHEMBL163474 | 0.81 | KDM4E (0.73) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL3310696 | 0.80 | KDM4E (0.71) | MEN1KMT2AALDH1A1MAPTKDM4E | |
| Hydrochloric Acid SCHEMBL11586082 | 0.79 | KDM4E (0.44) | MEN1KMT2AAPAF1TDP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | claimed |
| EP-1917246-B1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | claimed |
| EP-1917246-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | Novartis AG (CH) | 2008-05-07 | — | — | EP | claimed |
| WO-2007020046-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | claimed |
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | NOVARTIS AG (CH) | 2010-07-01 | — | — | US | disclosed |
| US-20100022565-A1 | PHARMACEUTICAL COMPOSITIONS | BUHL THOMAS | 2010-01-28 | — | — | US | disclosed |
| EP-2124893-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A CALCILYTIC AGENT | Novartis AG (CH) | 2009-12-02 | — | — | EP | disclosed |
| EP-1917246-B1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008107390-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING A CALCILYTIC AGENT | NOVARTIS AG (CH) | 2008-09-12 | — | — | WO | disclosed |
| EP-1964548-A1 | Pharmaceutical compositions comprising a calcilytic agent | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| EP-1917246-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | Novartis AG (CH) | 2008-05-07 | — | — | EP | disclosed |
| WO-2007020046-A1 | BENZOQUINAZOLINE DERIVATIVES AND THEIR USE IN TREATING BONE DISORDERS | NOVARTIS AG (CH) | 2007-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022565-A1 | PHARMACEUTICAL COMPOSITIONS | PTH1R, CALCA, CALCR | MEN1 42/4885KMT2A 4840/4885APAF1 1768/4885 |
| US-20100166765-A1 | BENZOQUINAZOLINE DERIVATIVES | CACNA1A, BMP4, TPX2 | MEN1 904/4885KMT2A 2241/4885APAF1 2895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.